Literature DB >> 19447312

Renal complications in oncologic patients.

Melissa L Givens1, Joy Wethern.   

Abstract

Acute renal failure (ARF) can be one of the many complications associated with malignancy and, unfortunately, often harbors a worse prognosis for the afflicted patient. Insult to the kidneys can occur for a variety of reasons in the oncologic patient. This article focuses on several of these etiologies, such as tumor lysis syndrome (TLS) and thrombotic microangiopathy (TMA), which are unique threats faced by the oncologic patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447312     DOI: 10.1016/j.emc.2009.01.001

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  4 in total

1.  Evaluation of electrolyte repletion in hematopoietic cell transplant patients receiving H-2 receptor antagonists or proton pump inhibitors.

Authors:  K Smith; M L Gatesman; S E Harpe; W Clark
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

2.  Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Authors:  Jorge Cortes; Joseph O Moore; Richard T Maziarz; Meir Wetzler; Michael Craig; Jeffrey Matous; Selina Luger; Bimalangshu R Dey; Gary J Schiller; Dat Pham; Camille N Abboud; Muthuswamy Krishnamurthy; Archie Brown; Abderrahmane Laadem; Karen Seiter
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

Review 3.  Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.

Authors:  F Scotté; J B Rey; V Launay-Vacher
Journal:  Support Care Cancer       Date:  2012-09-09       Impact factor: 3.603

4.  Acute kidney injury in cancer patients: A nationwide survey in China.

Authors:  Juan Jin; Yafang Wang; Quanquan Shen; Jianguang Gong; Li Zhao; Qiang He
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.